Latest Intelligence on Genitourinary and Osteoporosis in Europe

Published within

« | 1 | 2 | 3 | 4 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Wyeth: diversity key to growth

Wyeth's performance in 2002 was negatively affected by its heavy reliance on its Women's Health franchise. With the anticipated launch of Flumist, it is expected that 2003 will mark the beginning of Wyeth's transition from a reliance on HRT treatments to a more diversified portfolio.<BR />

Published By Datamonitor
05 Jun 2003
CommentWire
CommentWire

Johnson & Johnson: contraceptive patch to shake up market

The continuing rollout of J&J's Evra marks an important development in the $4 billion hormonal contraception market. Oral pills have dominated the market for more than 40 years, but with competitive pricing, convenient dosing and the support of family planning organizations, the consumer friendly patch could shake everything up.

Published By Datamonitor
18 Jun 2003
CommentWire
CommentWire

HRT: study kicks market when it's down

The UK Million Women study has confirmed that current or recent users of all types of HRT face an increased risk of developing breast cancer. The HRT market is already depressed after the findings of last year's Women's Health Initiative (WHI) in the US. This study is likely to spell the end of long-term HRT use.<BR />

Published By Datamonitor
08 Aug 2003
CommentWire
CommentWire

Osteoporosis: new drugs pushing for European entry

Last week saw two significant events in the European osteoporosis market: a proposed British launch date for Lilly's [LLY] Forsteo was revealed, and Roche [ROCZ.S]/GSK's [GSK.L] Boniva was recommended for approval. Both products would add much needed weight to the battery of osteoporosis drugs currently available in Europe, but challenges remain in terms of price and physician awareness.

Published By Datamonitor
28 Oct 2003
CommentWire
CommentWire

Lilly ICOS: Cialis third to tango

Lilly ICOS' Cialis joins Bayer [BAY.F]/GSK's [GSK.L] Levitra and Pfizer's [PFZ.L] Viagra in the fight against erectile dysfunction after receiving FDA approval earlier this month. Although Cialis offers several advantages over rival products, Lilly ICOS will have to go head-to-head with the leading players. This makes the adoption of effective promotional campaigns vital for success.

Published By Datamonitor
27 Nov 2003
CommentWire
CommentWire

Ferring: strong R&D base for next generation incontinence treatment

Ferring's next generation of antidiuretics to treat urinary incontinence could make use of pioneering research by Nobel Laureate Professor Agre. The company's close relationship with academia and its own long history of research in the urinary incontinence field should strengthen its position as a leading urology player.

Published By Datamonitor
01 Mar 2004
CommentWire
CommentWire

Roche/GSK: monthly formulation puts Boniva in pole position

The green light for Boniva sees it join Merck & Co's [MRK] Fosamax and Aventis's [SNY] Actonel as the newest member of the bisphosphonate family - a class of drugs that treat osteoporosis by increasing bone mineral density. Adherence to bisphosphonate regimens can be difficult for many patients, but Boniva's monthly formulation offers a major advance in overcoming this issue.

Published By Datamonitor
30 Mar 2005
CommentWire
CommentWire

Novartis: Prexige launches in the UK

More than two years since its initial approval, Novartis' COX-2 anti-inflammatory Prexige has been launched in the UK. Backed by leading British research and positive data from a number of recent clinical trials, the drug should experience a good uptake in the UK, which will no doubt be reflected across Europe when it hits continental markets this year.

Published By Datamonitor
20 Jan 2006
CommentWire
CommentWire

Vernalis/Endo: gain in menstrual migraine

New phase III data have confirmed previous results showing Vernalis and Endo's Frova to be an effective preventative treatment for menstrual migraine. This should pave the way for the migraine drug's approval in this additional indication. Anticipated in 2007, this approval is then expected to transform Frova's sales significantly.

Published By Datamonitor
08 May 2006
CommentWire
CommentWire

Sanofi-Aventis/Procter & Gamble: Actonel approved for men

Sanofi-Aventis and Procter & Gamble's Actonel has been given the green light for the treatment of male osteoporosis in the EU and US. This new indication for Actonel is good news for both companies, but the drug will still have to compete with Merck & Co's Fosamax, which is by far the biggest-selling therapy in the osteoporosis market.

Published By Datamonitor
18 Aug 2006

« | 1 | 2 | 3 | 4 | » »|

No help is available.